A change for Prima BioMed (ASX:PRR) with the company seeking shareholder support to adopt a new name, Immutep.
In a letter to shareholders in advance of its annual general meeting in November, the company's chair, Lucy Turnbull AO, said the change follows its 2014 acquisition of Immutep and subsequent sale under license of its former cancer vaccine CVac to Sydys Corporation.
According to Ms Turnbull, Immutep is already an established subsidiary of the Prima BioMed group.
"Many of our clinical partner associations are with Immutep and several patents remain registered under the . Immutep name," she said. "More apparent is Immutep’s strong association with LAG-3 and its founder, Dr Frederic Triebel, who is also our Chief Scientific Officer and Chief Medical Officer."
She continued, "Your Board therefore feels that the name Immutep more closely aligns with our principal activities and corporate identity. It also means costs associated with the name change and any disruption to our business will be minimal."
The company's new name, if approved by shareholders, will be quickly adopted with new branding and website.
"We see this as an important part of our efforts to promote and appropriately position our highly prospective LAG-3 related asset portfolio to the industry and investment markets," added Ms Turnbull.